Nitamoon 60
Nitamoon 60 - Image 2
Nitamoon 60 - Image 3
,

Nitamoon 60

Contains: Nateglinide BP 60 mg
Therapeutic Class: Meglitinide Class – Short-acting Insulin Secretagogue
Schedule: Schedule H (Prescription Drug)

Nitamoon 60 contains Nateglinide, an oral antidiabetic agent that belongs to the meglitinide class. It stimulates rapid and short-duration insulin secretion from pancreatic β-cells in response to meals, thereby effectively controlling postprandial blood glucose (PPG) levels in patients with Type 2 Diabetes Mellitus (T2DM).

Its rapid onset and short half-life provide glucose-dependent insulin release, with reduced risk of prolonged hypoglycemia, making it suitable for early T2DM and patients with erratic meal patterns.

Usage of Nitamoon 60

  • Type 2 Diabetes Mellitus

    • As monotherapy in early or mild cases

    • As add-on to metformin in patients with predominant postprandial hyperglycemia

    • In elderly patients or those at risk of hypoglycemia

    • Useful for patients with flexible mealtime habits

    • Can be an alternative to sulfonylureas in patients who need shorter-acting agents

Mechanism of Action

Nateglinide closes ATP-dependent potassium channels in pancreatic β-cells, leading to depolarization and calcium influx, which stimulates insulin secretion.
Unlike sulfonylureas, it mimics first-phase insulin response and is glucose-dependent, thereby reducing hypoglycemia risk.

Common Side Effects

  • Mild hypoglycemia (less than sulfonylureas)

  • Upper respiratory tract infections

  • Headache

  • Dizziness

  • Gastrointestinal discomfort (rare)

Most side effects are mild and transient.

Precautions

  • Use caution in patients with hepatic impairment (dose adjustment may be needed)

  • Not recommended in Type 1 diabetes or diabetic ketoacidosis

  • Avoid in patients with severe renal impairment (eGFR <30 mL/min)

  • Ensure regular meal timing to avoid hypoglycemia

  • Use with caution in elderly patients

Drug Interactions

  • Beta-blockers: May mask symptoms of hypoglycemia

  • Gemfibrozil: Can increase plasma levels of Nateglinide

  • NSAIDs, salicylates, MAOIs: May potentiate hypoglycemia

  • Diuretics, corticosteroids, thyroid products: May counteract hypoglycemic effects

  • Avoid with sulfonylureas or insulin unless closely monitored

Dosage and Administration

  • 60 mg or 120 mg before each major meal

  • Dose depends on glycemic response and HbA1c level

  • Take 1–30 minutes before meals to synchronize with food-induced glucose spikes

  • If a meal is skipped, skip the dose

Storage

  • Store below 25°C, away from light and moisture

  • Keep out of reach of children

Patient Counselling Tips

  • Take just before meals—not after or too early

  • Do not skip meals after taking the dose

  • Report signs of hypoglycemia: sweating, palpitations, shakiness

  • Regular blood sugar monitoring is important

  • Inform your physician about all other medications

Positioning Advantage

  • Faster onset and shorter duration than sulfonylureas

  • Ideal for early diabetes with meal-related glucose spikes

  • Lower risk of sustained hypoglycemia

  • Useful in elderly, busy professionals, or patients with variable meal times

Related products

Review My Order

0

Subtotal

Taxes & shipping calculated at checkout

Checkout